Biotech Values

[DewDiligence]

USPTO issues sialylation patent licensed to MNTA:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-issuance-u-123000304.html

Momenta Pharmaceuticals…today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,470,318, entitled "Polypeptides With Enhanced Anti-inflammatory and Decreased Cytotoxic Properties and Related Methods," to The Rockefeller University. Momenta is the exclusive licensee of the patent. The patent claims methods of inhibiting inflammation using intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions and expires in 2028.

This is the IP protection MNTA needed to continue pursuing the sialylated-IVIG program.